Only one phase 1 trial was registered in ClinicalTrials.gov (NCT04887935), which aims to investigate the safety of dapagliflozin, one type of SGLT2 inhibitor, for men considered at high risk of prostate cancer. The gene discussed is SLC5A2; the disease is prostate cancer.